DSGN DESIGN THERAPEUTICS INC

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York.

A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will be archived for at least 30 days following the presentation.

About Design Therapeutics

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:

Renee Leck

THRUST Strategic Communications

 



EN
27/08/2025

Underlying

DSGNDESIGN THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DESIGN THERAPEUTICS INC

 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics to Participate in the 2025 Cantor Global Healthcar...

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York. A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will be...

8h / 53m 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs ...

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 in FA Patients Underway Phase 2 Biomarker Study for DT-168 Initiated in Patients with Fuchs Endothelial Corneal Dystrophy (FECD) Cash and Securities of $216.3 Million Support Continued Pipeline Advancement CARLSBA...

August 7, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosin...

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites CARLSBAD, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for s...

June 4, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare...

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference CARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present during the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York. A live webcast of the presentation will be available and in the investors section of the company’s website at . The webcast will be archived for at least 30 ...

May 28, 2025 1 EN
 PRESS RELEASE
Free
DSGN DESIGN THERAPEU...

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthc...

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will ...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch